Primary Immunodeficiency clinical trials at UC Health
1 in progress, 0 open to new patients
Safety, Tolerability, Efficacy, and Pharmacokinetic Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Sorry, in progress, not accepting new patients
This is a Phase 3, multicenter, open-label study of safety, tolerability, efficacy, and pharmacokinetics (PK) of ProMetic's Immune Globulin Intravenous (Human) 10% (Prometic IGIV 10%, the investigational medicinal product [IMP]), in Adults and Children with Primary Immunodeficiency Diseases (PIDD).
at UC Irvine